linjc16/ctgov huggingface dataset:
Serum Presepsin as Early Predictor for Neonatal Early-onset Sepsis

Study Overview
=================
Brief Summary
-----------------
124 neonates aged ≤7 days with suspected EOS were clinically evaluated using SNAP-II and gave blood samples for BC, total leucocytic count (TLC), lymphocytic and neutrophil count, and ELISA estimation of serum levels of PSP, procalcitonin (PCT), and tumor necrosis factor-α (TNF-α). Enrolled neonates were categorized as Confirmed EOS: neonates with evident clinical sepsis manifestations and positive BC, Suspected EOS: neonates with evident clinical sepsis manifestations but had negative BC and No EOS included neonates free of evident clinical sepsis manifestations, had negative BC and showed no deterioration till 72-hr after admission.

Official Title
-----------------
At Admission Serum Presepsin as Early Predictor for Disease Severity and Positive Blood Culture for Neonates With Early-onset Sepsis

Conditions
-----------------
Neonatal Sepsis

Intervention / Treatment
-----------------
* Diagnostic Test: Serum Presepsin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: included gestational age (GA) of 28-41 weeks and 5-min APGAR score of ≥7, and neonatal age of <7 days Exclusion Criteria: including small for gestational age, presence of a chromosomal abnormality, multiple congenital anomalies, genetic syndromes, history of premature rupture of membranes, chorioamnionitis, neonatal asphyxia, and missed inclusion criterion.

Ages Eligible for Study
-----------------
Minimum Age: 1 Day
Maximum Age: 7 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: EOS<br> | Diagnostic Test: Serum Presepsin<br>* Estimation of Serum Presepsin at time of admission<br>|
| No Intervention: NO-EOS<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prediction of neonatal outcome | Ability of Serum Presepsin to disseminate neonates with confirmed EOS | one week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Early-onset neonatal sepsis, Presepsin, Clinical scoring, Early predictors, Blood culture
Clinical and Sonoelasographic Evaluation of the Elasticity of the Uterine Cervix in Pregnant Patients at Term

Study Overview
=================
Brief Summary
-----------------
In this study the investigators aim to compare the cervical dilation time in pregnant patients at term who had clinical evaluation of the cervical consistency with patients who had also quantitative measurement of the cervical elasticity in .

Detailed Description
-----------------
Softening of the uterine cervix in pregnant patients at term is usually evaluated clinically by subjective vaginal manual examination (Bishop's score).One of the variables of the score is cervical consistency which is considered important factor.The cervical consistency is described as soft,medium or stiff.However, the digital assessment of consistency is subjective and less reproducible.The Bishop's score also gives information about expected duration of labor after induction. The consistency of the uterine cervix can also be evaluated objectively sonoelastographically by measuring the cervical elasticity.This is illustrated by a color map, where low stiffness (soft tissue) is indicated in red, middle stiffness is in green and high stiffness (hard tissue) is in blue.In this study we aim to compare the cervical dilation time between the clinical evaluation of the cervical consistency and the quantitative measurement of the cervical elasticity in pregnant patients at term.

Official Title
-----------------
Clinical and Sonoelasographic Evaluation of the Elasticity of the Uterine Cervix in Pregnant Patients at Term

Conditions
-----------------
Pregnancy

Intervention / Treatment
-----------------
* Device: Acuuvix SonoAce UGEO


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant patients at term Exclusion Criteria: Various pregnancy complications

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 44 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Acuuvix SonoAce UGEO|Ultrasonographic vaginal examination|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess elasticity of uterine cervix through comparison of sonoelastographic evaluation and manual vaginal examination [Bishop Score] in pregnant patients at term |  | at time of the manual vaginal examination and participants will be followed for the duration of hospital stay, an expected average of 5 weeks |
HIV/AIDS & Alcohol-Related Outcomes: Translational Evidence-Based Interventions

Study Overview
=================
Brief Summary
-----------------
A clinical study for patients with HIV that investigates the best way to reduce HIV transmission risk, and to improve the overall health of people living with HIV/AIDS. Participants will complete four assessments over the course of one year and will be randomly assigned to a five-week treatment program.

Detailed Description
-----------------
The main purpose of this research study is to investigate the best way to reduce HIV transmission risk and to improve the overall health of people living with HIV/AIDS. This study tests an intervention program that aims to improve knowledge, motivation, and skills. The intervention program is designed to motivate participants to take their medications routinely, improve the quality of life for those living with HIV, and decrease risky behaviors that may lead to HIV transmission.

Official Title
-----------------
HIV/AIDS & Alcohol-Related Outcomes: Translational Evidence-Based Interventions

Conditions
-----------------
HIV/AIDS

Intervention / Treatment
-----------------
* Behavioral: WELL Program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HIV positive Recent alcohol use Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: WELL Program<br>Five-week treatment program that aims to improve knowledge, motivation, and skills. It is designed to motivate participants to take their medications routinely, improve the quality of life for those living with HIV, and decrease risky behaviors that may lead to HIV transmission. | Behavioral: WELL Program<br> <br> |
| No Intervention: Standard of Care<br>Five-week standard of care program. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Viral load | The primary outcome measure will be disease progression or more specifically, the proportion of patients achieving viral suppression. | Change from baseline at 3 months, 6 months and 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
behavior, hiv, skills, aids, alcohol, health, knowledge, motivation
Prognostic Model of HCV-related Disease Progression After DAAs

Study Overview
=================
Brief Summary
-----------------
In this study, the investigator would conduct an ambispective cohort study to build a prediction model of HCV-related disease after DAAs.

Detailed Description
-----------------
The emergence of direct antiviral agents (DAAs) makes it possible to cure HCV, and the sustained virological response (SVR) rate is up to 90% after DAAs therapy. However, the acquisition of SVR does not mean the cure of HCV-related diseases, some patients still developed liver cirrhosis, liver cancer and other diseases after achived SVR by DAAs therapy.In this study the investigator would like to bulid a prediction model of HCV-related disease after DAAs by conducting an ambispective cohort study. The participants of this study would be adult patients (≥18 years old) with chronic HCV infection and have received DAA therapy, the investigator would retrospectively collected DAA therapy-related information, and follow-up all the enrolled participants every 6 months to observe their liver-related disease outcomes (composite liver outcome, including liver-related deaths, hepatocellular carcinoma, liver decompensation, and liver transplantation).

Official Title
-----------------
Prognostic Model of HCV-related Disease Progression After DAAs

Conditions
-----------------
HCV

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult patients (≥18 years old) with chronic HCV infection that were HCV RNA positive; have received DAA treatment; would like to adhere to the follow-up Exclusion Criteria: lack of HCV treatment information;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of composit liver-related events | Composite liver outcomes, including liver-related deaths, hepatocellular carcinoma, liver decompensation, or liver transplantation. | through study completion, an average of 2 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HCV
Use of MiniMed 780G System in Children and Adolescents

Study Overview
=================
Brief Summary
-----------------
Hybrid closed-loop technology have shown that it improves glycemic control parameters, but the investigators do not have sufficient data at more than 6 months of follow-up, allowing us to describe the effectiveness of these systems in the long term. All MiniMed 780G system users from November 2020 to March 2022 were included (n=32) For every time points, there was a significant difference in Time In Range between the pre-AHCL and post-AHCL. Noted difference were +14.5% and, +10.8% at respectively 3 months and 1 year. No more hypoglycemia were identified. This real-life analysis shows that the algorithm is effective in improvement of metabolic control for T1 diabetic children and adolescents, at one year of follow-up. However, an effect of breathlessness is observed which underlined the need for a solid therapeutic education program.

Official Title
-----------------
Use of MiniMed 780G System in Children and Adolescents, a French Real Life Observational Study

Conditions
-----------------
Diabetes

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: All children with type 1 diabetes in whom a Medtronic G780 closed-loop pump was placed between November 2020 and March 2022 in our center were included. Exclusion criteria: Participant opposition

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glycated hemoglobin | Percentage of glycated hemoglobin measured by the MiniMed 780G system | 1 year | 
| Time spent in range Level with glucose levels within the norm | Time spent with glucose levels between 70 and 180 mg/dL | 1 year | 
| Time spent with glucose levels below range | Time spent with glucose levels inferior to 70mg/dL | 1 year | 
| Time spent with glucose levels above range | Time spent with glucose levels superior to 180 mg/dL | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Advanced hybrid closed loop, pediatrics, real-world, time in range
Dextrose Infusion by Burettes Versus Dextrose Boluses in Prevention of Neonatal Hypoglycemia

Study Overview
=================
Brief Summary
-----------------
NULL HYPOTHESIS • There is no difference in the incidence of hypoglycemia among preterms receiving either two hourly 10% dextrose boluses or 10% dextrose infusion by burettes during the 72 hours of admission in Special Care Unit- Mulago Hospital. ALTERNATE HYPOTHESIS • Use of two hourly 10% dextrose boluses increases the incidence of hypoglycemia by 30% compared to 10% dextrose infusion by burettes among preterms admitted to Special Care Unit in the first 72 hours of admission.

Official Title
-----------------
Dextrose Boluses Versus Dextrose Infusions by Burettes in Prevention of Hypoglycemia Among Preterms Admitted at Mulago Hospital: An Open Label Randomized Clinical Trial

Conditions
-----------------
Once a Preterm Developed Hypoglycemia, no More Blood Glucose Was Measured During the Study Period.

Intervention / Treatment
-----------------
* Drug: 10% dextrose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - SELECTION CRITERIA Inclusion criteria Preterms whose care givers/ mothers gave informed consent Preterms whose age was < 24 hours of life Preterms with birth weight ≥1kg Preterms with random blood sugar ≥ 2.6 mmol/l at admission into SCU. Exclusion Criteria Absence of a biological mother or abandoned baby Presence of gross congenital abnormalities. Very sick (Apgar score ≤ 5 at 5 minutes

Ages Eligible for Study
-----------------
Maximum Age: 24 Hours

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Bolus arm<br>two hourly dextrose boluses administered via an intravenous cannula | Drug: 10% dextrose<br> <br> |
| Experimental: infusion<br>10% dextrose infusion by burettes | Drug: 10% dextrose<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence proportion of hypoglycemia |  | 3months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| survival measured as a proportion |  | 3months |
Postoperative Dose of Parathyroid Hormone as a Marker for the Occurrence of Hypoparathyroidism After Total Thyroidectomy

Study Overview
=================
Brief Summary
-----------------
The main objective of this study is to establish an optimal threshold Early parathormon (PTH) assay in order to exclude hypoparathyroidism , that is to say to obtain a negative predictive value of hypoparathyroidism highest possible.

Official Title
-----------------
Diagnostic Value of Immediate Postoperative Dose of Parathyroid Hormone as a Marker for the Occurrence of Hypoparathyroidism After Total Thyroidectomy: A Retrospective Observational Study

Conditions
-----------------
Hypoparathyroidism

Intervention / Treatment
-----------------
* Biological: immediate post operative bioassay of Parathyroid Hormone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients consecutively operated on between February 1, 2012 and December 1, 2013 Total thyroidectomy +/- lymphadenectomy Respect of clinicobiological protocol presented above The ( the ) patient ( e) was informed ( e) on the implementation of the study 's objectives, constraints and patient rights The ( the ) patient ( e) is under ( e) at least 18 years Exclusion Criteria: The ( the ) patient ( e) is under guardianship, curatorship or under guard saves justice It is not possible to give to ( the ) patient ( e) informed information History of cervical radiotherapy Previous history of dysfunction of the parathyroid glands Previous history of surgery of the parathyroid glands A history of kidney failure or hepatocellular History of osteomalacia or Paget's disease unhealed cancer antecedent History of sarcoidosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with total thiroidectomy<br> | Biological: immediate post operative bioassay of Parathyroid Hormone<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the presence/absence of hypoparathyroidism | hypoparathyroidism is defined as: corrected serum calcium Day 1 <1.90 and / or symptoms of hypocalcemia (cramps, tingling of the extremities and peri-oral) to Day 1 authenticated by a VAS score> 3. | day 1 |
Epidemiological Study in FRONtoTemporal Dementia

Study Overview
=================
Brief Summary
-----------------
An international, multicenter, epidemiological observational study aims to investigate the prevalence of genetic etiologies in patients diagnosed with FTD or clinically suspected for FTD.

Detailed Description
-----------------
Frontotemporal dementia (FTD) is a genetically and pathologically heterogeneous neurodegenerative disease caused by the loss or damage of nerve cells in the brain's frontal and temporal lobes. This leads to abnormalities in behaviour, personality, and language comprehension problems. Also, people with FTD show movement disorders like tremor, rigidity, difficulty in coordination, muscle spasms and weakness. FTD's etiology is sporadic or heritable. Sixty to 70% of FTD cases are sporadic, while 30 to 40% are inherited (familial aggregation). For this study, blood samples were collected from clinically diagnosed or suspected FTD patients and were analysed for a broad range of pathogenic variants in genes associated with FTD. The scientific insights acquired from this study will help identify novel therapeutic targets and develop/ investigate potential disease-modifying drugs.

Official Title
-----------------
Epidemiological Study in FRONtoTemporal Dementia

Conditions
-----------------
Frontotemporal Dementia

Intervention / Treatment
-----------------
* Diagnostic Test: Genetic Screening


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Informed consent, which includes reference to the genetic testing, is obtained from the participant/legal guardian The participant is aged between 25 to 85 years The participant is diagnosed with Frontotemporal dementia (FTD) or has signs or symptoms of FTD

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Participants diagnosed with Frontotemporal Dementia<br>Participants diagnosed with Frontotemporal Dementia | Diagnostic Test: Genetic Screening<br>* Blood samples will be collected from clinically diagnosed or suspected FTD patients and will be analysed for a broad range of pathogenic variants in genes associated with FTD.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To investigate the prevalence of genetic etiologies in FTD by genotyping FTD participants/ FTD suspected participants |  | 15 months |
Exploration of Fatigue, Uncertainty, Depression and Quality of Life in Heart Transplantation Recipients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to explore the fatigue, uncertainty, depression and quality of life in heart transplant recipients, and associated factors of quality of life .

Detailed Description
-----------------
The purpose of this study is to explore the symptom distress, fatigue, depression, uncertainty, and quality of life in heart transplant recipients, and associated factors of quality of life (QOL). The eligible patients are (1)who undergone heart transplantation were recruited from the Department of Cardiac Surgery, Nation Taiwan University Hospital,(2)18 year old or older. A set of questionnaire with the Transplant Symptom Frequency and Symptom Distress Scale, Hospital Anxiety and Depression Scale (HADS) , Fatigue Symptom Inventory (FSI), Mishel's Uncertainty Scale, and 12-item Short-Form Health Survey (SF-12) were used to collected symptom distress, fatigue, depression, uncertainty, and QOL .

Official Title
-----------------
Exploration of Fatigue ,Uncertainty ,Depression and Quality of Life in Heart Transplantation Recipients

Conditions
-----------------
Heart Transplantation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical diagnosis of heart transplantation Adults 18 years of age Exclusion Criteria: The woman who are pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| heart transplantation<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The SF12 Health survey | It was used to measure quality of life | 1 month | 
| Transplant Symptom Frequency and Symptom Distress Scale | it was used to measure symptom distress. | 1 week | 
| Fatigue Symptom Inventory | It was used to measure level of fatigue. | 1 week | 
| Hospital Anxiety and Depression Scale (HADS) | It was used to measure level of anxiety and depression. | 1month | 
| Illness Uncertainty Scale | It was used to measure level of uncertainty. | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Heart Transplantation, Symptom Distress, Fatigue, Depression, Quality Of Life.